Result for
Topic: Vaccines and Immunity
January 29, 2021
Duration of SARS-CoV-2 Sero-Positivity in a Large Longitudinal Sero-Surveillance Cohort The COVID-19 Community Research Partnership
[Pre-print, not peer-reviewed] Follow-up of 11,468 adults with mild or asymptomatic COVID-19 infection found that serological evidence of previous infection, specifically the presence of either IgG or IgM antibodies, waned quickly over time, with roughly 50% of people undergoing sero-reversion within 30 days of their initial positive test. The rate of sero-reversion was not associated…
The effectiveness of the first dose of BNT162 b 2 vaccine in reducing SARS-CoV-2 infection 13-24 days after immunization real-world evidence
[Pre-print, not peer-reviewed] The first dose of the BNT162b2 mRNA COVID-19 vaccine (Pfizer–BioNTech) is associated with an approximately 51% reduction in the incidence of PCR-confirmed SARS-CoV-2 infections at 13 to 24 days after immunization compared to the rate during the first 12 days. These findings are based on a retrospective cohort study in Israel (December…
SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines
[Pre-print, not peer-reviewed] Using a lentivirus-based pseudovirus assay, the SARS-CoV-2 B.1.1.7 (UK) variant was shown to exhibit only modestly reduced susceptibility to neutralization from convalescent sera (1.5-fold average reduction) and sera from recipients of both the Moderna and Novavax vaccine phase 1 studies (2-fold average reduction after two inoculations. The authors used the prototypic D614G…
Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial
[Press release, not peer-reviewed] The Johnson and Johnson single-dose COVID-19 candidate vaccine had 66% efficacy against moderate to severe COVID-19, based on a press release describing the phase 3 clinical trial results from the ENSEMBLE trial. Among all participants including those infected with an emerging viral variant the vaccine prevented moderate to severe COVID-19 28…
January 28, 2021
Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial
[Press release, not peer-reviewed] Preliminary results for phase 2/3 trials for the recombinant protein-based COVID-19 vaccine NVX-CoV2373 made by Novavax showed up to 89.3% efficacy in the UK cohort (n= >15,000), where 56 participants in the placebo group developed COVID-19 vs 6 in the vaccine group. Of note, the B.1.1.7 variant was observed in 32…
Neutralization of Spike 6970 Deletion E484K and N501Y SARS-CoV-2 by BNT162b2 Vaccine-Elicited Sera
[Pre-print, not peer-reviewed] Sera from recipients who completed the 2-dose regimen of the Pfizer vaccine BNT162b2 (n=20) had similar neutralizing geometric mean titers (GMTs) against SARS-CoV-2 viruses engineered to contain key spike protein mutations from variants emerging from the UK (B.1.1.7) and South Africa (B.1.351) compared to GMTs against the wild-type virus. Compared to the…
U.S. Public Views about COVID-19 “Immunity Passports
[Pre-print, not peer-reviewed] A nationally representative online survey of 1,315 US adults conducted in June 2020 found that 45% of respondents supported some form of immunity privileges. Among the forms, private certificates were favored over government-issued immunity passports (48% vs 43%). Respondents were more likely to justify immunity privileges for high-risk jobs or to attend…
January 27, 2021
SARS-CoV-2 Recruits a Haem Metabolite to Evade Antibody Immunity
A molecular study of SARS-CoV-2 found that the virus’s spike protein was able to bind to biliverdin and bilirubin, products of heme metabolism. The authors identified the phenomenon after observing a green pigment in protein precipitate of recombinant SARS-CoV-2 spike produced in human cell lines. Binding to biliverdin inhibited the ability of immune sera and…
Non-Congruent SARS-CoV-2 Waves in England
A study of SARS-CoV-2 infection waves in England noted different regional distributions of infections during the first (March-September 2020) and second (September 2020-onward) waves, with regions that experienced high mortality in the first wave experiencing lower mortality in the second. Greater first wave severity was also associated with slower second wave growth rate. Possible explanations…
Trends Regional Variation and Clinical Characteristics of COVID-19 Vaccine Recipients a Retrospective Cohort Study in 23.4 Million Patients Using OpenSAFELY
[Pre-print, not per-reviewed] A retrospective cohort study of electronic health record data from the National Health System in England from 23.4 million patients using the OpenSAFELY-TPP platform found that between December 8 and January 13, 2021, a total of 961,580 people received a COVID-19 vaccine. Of 1,160,062 patients aged 80 or over and not living…
Previous page Next page